



Proteomics International

LABORATORIES LTD

ASX Release

12 May 2022

ASX code: PIQ

Proteomics International awarded \$400,000 to support manufacturing capability in Australia

- **Proteomics International will receive \$413,516 funding to support manufacture of the PromarkerD test for diabetic kidney disease and other diagnostic tests in Australia**
- **Funding awarded by MTPConnect as part of the Australian Government's \$45 million BioMedTech Horizons program, a Medical Research Future Fund (MRFF) initiative**
- **Funding will be used to establish local manufacturing supply chains, quality assurance procedures and support the PromarkerD application for TGA approval**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has been awarded \$413,516 funding to support the manufacture of its PromarkerD clinical diagnostic test in Australia - the world's first predictive diagnostic test for diabetic kidney disease.

The funding was awarded by MTPConnect as part of the Australian Government's \$45 million BioMedTech Horizons program, an initiative of the Medical Research Future Fund. The program aims to support innovative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key health challenges, and maximise entrepreneurship and idea potential.

Proteomics International managing director Dr Richard Lipscombe said the funding would supplement the Company's existing manufacturing strategy and budget. *"It will support future manufacture of the PromarkerD test for Australia and South-East Asia by building upon Proteomics International's specialised ISO 13485 Quality Control and Quality Assurance certification. We see enormous sales potential in this region once we complete local regulatory and reimbursement approvals. This funding will also help our activities towards obtaining TGA approval [ASX: 28 April] and registration of PromarkerD under the Medical Benefits Scheme [ASX: 22 February],"* he said.

Establishing specialised local manufacturing capability for PromarkerD will strengthen and diversify Proteomics International's supply chains for key reagents such as antibodies and recombinant protein standards. Importantly for the Company's diagnostics pipeline, it will also help launch future tests under development by Proteomics International, as well as potentially assist other diagnostics companies, bringing more novel Australian medical devices to market in this expanding area. The funding is to be spent over a 12 month period and Proteomics International will match the funds dollar for dollar, plus additional in-kind contributions.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

ENDS

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

About MTPConnect

Established in 2015 as an independent, not-for-profit organisation, MTPConnect is Australia's Medical Technologies and Pharmaceuticals (MTP) Industry Innovation Growth Centre, championing the growth of Australia's vibrant MTP ecosystem.

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com